ketorolac has been researched along with Cancer of Oropharnyx in 4 studies
Ketorolac: A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is an NSAID and is used principally for its analgesic activity. (From Martindale The Extra Pharmacopoeia, 31st ed)
ketorolac : A racemate comprising equimolar amounts of (R)-(+)- and (S)-(-)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid. While only the (S)-(-) enantiomer is a COX1 and COX2 inhibitor, the (R)-(+) enantiomer exhibits potent analgesic activity. A non-steroidal anti-inflammatory drug, ketorolac is mainly used (generally as the tromethamine salt) for its potent analgesic properties in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis. It was withdrawn from the market in many countries in 1993 following association with haemorrhage and renal failure.
5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid : A member of the class of pyrrolizines that is 2,3-dihydro-1H-pyrrolizine which is substituted at positions 1 and 5 by carboxy and benzoyl groups, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ketorolac has proved to be a safe alternative or addition to narcotics in other operations, but has not been thoroughly evaluated in TORS." | 1.62 | Evaluating the risks and benefits of ketorolac in transoral robotic surgery. ( Drejet, SM; Mantravadi, AV; Moore, M; Sandelski, MM; Sim, MW; Yesensky, JA; Zimmer, D, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sandelski, MM | 1 |
| Drejet, SM | 1 |
| Zimmer, D | 1 |
| Yesensky, JA | 1 |
| Moore, M | 1 |
| Mantravadi, AV | 1 |
| Sim, MW | 1 |
| Mulshine, JL | 2 |
| Atkinson, JC | 1 |
| Greer, RO | 1 |
| Papadimitrakopoulou, VA | 1 |
| Van Waes, C | 2 |
| Rudy, S | 1 |
| Martin, JW | 1 |
| Steinberg, SM | 1 |
| Liewehr, DJ | 1 |
| Avis, I | 1 |
| Linnoila, RI | 1 |
| Hewitt, S | 1 |
| Lippman, SM | 1 |
| Frye, R | 1 |
| Cavanaugh, PF | 2 |
| Khatami, M | 1 |
| Hong, SH | 1 |
| Ondrey, FG | 1 |
| Avis, IM | 1 |
| Chen, Z | 1 |
| Loukinova, E | 1 |
1 trial available for ketorolac and Cancer of Oropharnyx
| Article | Year |
|---|---|
Randomized, double-blind, placebo-controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Double-Blind Method; Female; Hum | 2004 |
3 other studies available for ketorolac and Cancer of Oropharnyx
| Article | Year |
|---|---|
Evaluating the risks and benefits of ketorolac in transoral robotic surgery.
Topics: Humans; Ketorolac; Oropharyngeal Neoplasms; Retrospective Studies; Risk Assessment; Robotic Surgical | 2021 |
Cyclooxygenase inhibitor ketorolac or mast cell stabilizers: immunologic challenges in cancer therapy.
Topics: Cyclooxygenase Inhibitors; Humans; Ketorolac; Leukoplakia, Oral; Mast Cells; Oropharyngeal Neoplasms | 2005 |
Cyclooxygenase regulates human oropharyngeal carcinomas via the proinflammatory cytokine IL-6: a general role for inflammation?
Topics: Animals; Antibodies; Arachidonic Acid; Cell Division; Clinical Trials, Phase II as Topic; Culture Me | 2000 |